The contents of total phenolic acids and rosmarinic acid were determined and the antiplatelet potential assessed of extracts of lemon balm (Melissa officinalis L., Lamiaceae) leaf samples collected during 2014 and 2015. The quantity of total phenolic acids ranged from 4.8 to 8.5%, while the rosmarinic acid content ranged from 1.78 to 4.35%. Results of statistical analysis showed that the undiluted extracts have antiplatelet activity in the ADP test (final concentration 31.25 mg/L). While there are reports on antiplatelet activity of lemon balm essential oil, to the best of our knowledge, this is the first report on antiplatelet activity of lemon balm leaf extracts.
Lemon balm (Melissa officinalis L., Lamiaceae) is an endogenous plant of western Asian regions and the Eastern Mediterranean, and is cultivated in almost all of Europe and North America [1] . It grows as a shrub, 0.3 to 0.9 m high, usually with several stems. The major chemical constituents are polyphenolic acids namely rosmarinic (most abundant), p-coumaric, caffeic and chlorogenic acids. Lemon balm essential oil (0.02-0.37%) is composed of more than 40% monoterpenes and more than 35% sesquiterpenes [2] . Other constituents determined in leaf samples include flavonoids, tannins and triterpenes [3] . Externally, lemon balm extracts are used for symptomatic treatment of herpes labialis while orally applied extracts act as a carminative and a sedative [1] .
Antiplatelet activity, i.e. prevention of platelet aggregation, of polyphenols is of interest as it has been shown that they can act in submicromolar concentrations on platelet aggregation. This is a useful characteristic as polyphenols could serve as new sources of antiaggregatory drugs in prevention of cardiovascular diseases (e.g. prevention of thrombosis, heart attack or stroke). On the other hand, polyphenols from everyday diet could interfere with platelet functional tests and subsequently hinder diagnosis of platelet related disorders [4] . It has been shown that lemon balm essential oil has antiplatelet activity [5] that can be attributed to major terpene constituents [6, 7] . As major constituents of lemon balm leaves are phenolic acids, primarily rosmarinic acid, the objective of this work was to determine the contents of total phenolic acids and rosmarinic acid, and the antiplatelet activity of ethanolic lemon balm leaf extracts.
Total phenolic acid concentrations ranged from 4.8 to 8.5% (Table  1) fulfilling the requirements of European Pharmacopeia (more than 4% of phenolic acids). Rosmarinic acid, as a major constituent, was determined by HPLC and its content ranged from 1.78 to 4.35% (Table 1) .
Lemon balm ethanolic extracts (non-diluted, 10%, 1%) were tested for antiaggregatory activity in a thrombocyte functional test induced with adenosine diphosphate (ADP). Statistical analysis (one-way ANOVA with post hoc Tukey test) of the results showed that only the undiluted extracts had antiplatelet activity in the test (Figure 1 ). Standard rosmarinic acid was analyzed in concentrations of 0.09, 0.9, 9 and 90 µM. Only 90 µM rosmarinic acid solution showed statistically significant reduction of platelet aggregation. Table 1 for concentrations). Platelet aggregation is expressed as percentage to the solvent control.
To the best of our knowledge this is the first report of antiplatelet effect of lemon balm leaf extracts. This activity can be attributed mainly to rosmarinic acid as all extracts showed antiplatelet activity at concentrations of 50-120 µM (based on HPLC results, % rosmarinic acid {(see Table 1 ) x concentration of extract (1 mg/mL) / M (rosmarinic acid, 360.3 g/mol)}, which is comparable with 90 µM concentration of rosmarinic acid in the antiplatelet test. Previously, lemon balm essential oil was shown to have an antiplatelet effect at a concentration of 4 µg/mL using collagen and thrombin as inducers of aggregation that was attributed to terpene constituents [5] . The lower results that we have observed can be attributed to the different chemical composition of the leaf extract compared with the essential oil. The advantage of our approach is that the analysis was on whole blood rather than platelet rich plasma used in the previous study [8] . 
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Determination of total phenolic acids:
The content of phenolic acids in the plant samples was determined by the official Eur. Ph. method [3] . Extracts were prepared by reflux extraction of 0.2 g of the powdered drug with 190 mL of ethanol (50%, v/v) for 30 min. Filtrate and washings were collected and diluted to 200 mL with diluted ethanol. Total phenolic acid content was determined by measuring the absorbance of the complex formed between phenolic acids and sodium nitrite -sodium molybdate at 505 nm [9] . The measurements were carried out using a Varian Cary 50 Bio spectrophotometer (Varian Inc., USA). The content of phenolic acids was expressed as the equivalent of rosmarinic acid based on 3 independent analyses.
HPLC analysis of rosmarinic acid:
Rosmarinic acid content was determined by reverse phase high performance liquid chromatography coupled with a diode array detector on an Agilent 1100 system (Agilent, USA) using the method described by Medić-Šarić et al. [10] . Extracts used for determination of phenolic acids were filtered (Whatman 0.22 µm syringe filter, Sigma Aldrich, USA). A Zorbax SB-C18 (250 mm x 4.6 mm, particle size 5 µm) column with precolumn (12.5 mm x 4.6 mm, particle size 5 µm) was used as the stationary phase. Elution was achieved with a gradient of mobile phases A (water, methanol and formic acid in ratio 93:5:2) and B (water, methanol and formic acid in ratio 3:95:2) following the timetable (t/min, %B): (0, 20), (10, 40) , (35, 50), (47, 50), (70, 80), (80, 20) . Detection was based on retention time and UV spectra compared with standard; quantification was based on calibration curves recorded at 254 nm.
Determination of antiplatelet activity:
Platelet aggregation was analyzed in whole blood utilizing a Multiplate ® impedance analyzer (Roche, Switzerland). Blood samples were obtained from 9 healthy volunteers with their written consent. This study has been approved by the ethical committee of the Croatian Institute of Transfusion Medicine. The following procedure was used for all analyses: 300 μL of blood was incubated at 37°C for 6 min with 20 μL of lemon balm extract solution and 300 μL of saline with CaCl 2 . Aggregation cascade was induced according to protocol by adding 20 μL of agonist ADP reagent (6.3 μM) [3] . Aggregation was measured for 6 min and expressed as area under the curve in arbitrary units (AU). Untreated samples (negative control, 100% of aggregation) were analyzed with 20 μL of solvent. All measurements were performed in triplicate. Final results for extracts were expressed as percentage of residual platelet aggregation compared with the untreated sample. Rosmarinic acid standard was used as positive control. Statistical analysis was performed using the Microsoft Office Excel 2003 (Microsoft Corporation, USA) program; p values lower than α = 0.05 were regarded as statistically significant.
